Trial Profile

A randomised, placebo-controlled, double-blind, parallel-group, multicentre, phase IIa study to explore the relationship between QTcF interval at first dose (loading dose) and at steady state after treatment with AZD1305 extended-release tablets or placebo when given to patients with documented atrial fibrillation.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jan 2012 Actual patient number (65) added as reported by ClinicalTrials.gov.
16 Nov 2011 Actual trial initiation date changed from 1 Mar 2008 to 21 Feb 2008.
01 Jun 2011 Results published in the American Journal of Cardiovascular Drugs.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com